Is our approach to thyroid nodules and differentiated thyroid carcinoma in agreement with the American guideline and European consensus?;¿Está de acuerdo nuestra conducta ante el nódulo tiroideo y cáncer diferenciado de tiroides con la guía norteamericana y el consenso europeo?

Endocrinologia y Nutricion

Volumn 57, Issue 8, 2010, Pages 357-363

  Gómez Sáez, José Manuel ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

American guideline in differentiated thyroid carcinoma; Differentiated thyroid carcinoma; European consensus in differentiated thyroid carcinoma; Thyroid nodules

Indexed keywords

IODINE 123; IODINE 131; THYROGLOBULIN;

ABLATION THERAPY; ARTICLE; CLINICAL PRACTICE; CYTOLOGY; ECHOGRAPHY; LYMPH NODE DISSECTION; PRACTICE GUIDELINE; QUESTIONNAIRE; SUBTOTAL THYROIDECTOMY; THYROID CARCINOMA; THYROID NODULE; THYROIDECTOMY; WHOLE BODY SCINTISCANNING;

CARCINOMA; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; CROSS-SECTIONAL STUDIES; DATA COLLECTION; DRUG UTILIZATION; ENDOCRINOLOGY; EUROPE; GUIDELINE ADHERENCE; HUMANS; IODINE RADIOISOTOPES; LYMPH NODE EXCISION; NEOPLASM STAGING; NUCLEAR MEDICINE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; RADIONUCLIDE IMAGING; SPAIN; THYROGLOBULIN; THYROID NEOPLASMS; THYROID NODULE; THYROIDECTOMY; THYROXINE; ULTRASONOGRAPHY; UNITED STATES; WHOLE BODY IMAGING;

EID: 77957264740     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/j.endonu.2010.05.008     Document Type: Article

References (27)

1. Guidelines for the Management of Thyroid Cancer in Adults 2002, Thyroid Cancer Guidelines Development Group, the British Thyroid Association & the Royal College of Physicians, The Publication Unit of the Royal College of Physicians, Londres.
2. Watkinson J.C. The British Thyroid Association guidelines for the management of thyroid in adults. Nucl Med Commun 2004, 25:897-900.
3. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. Endocr Practice. 2001;7:203-20.
4. Schlumberger M., Berg G., Cohen O., Duntas L., Jamar F., Jarzab B., et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: an European perspective. Eur J Endocrinol 2004, 150:105-112.
5. Sánchez Franco F. Directices para el tratamiento del carcinoma diferenciado de tiroides. Endocrinol Nutr 2005, 52:23-31.
6. Gómez J.M., Gómez N., Sahún M., Rafecas A., Villabona C., Soler J. Validity for risk group definition in differentiated thyroid carcinoma. End Rel Cancer 1997, 4:459-464.
7. Ringel M.D., Ladenson P.W. Controversies in the follow-up and management of well-differentiated thyroid cancer. End Rel Cancer 2004, 11:97-116.
8. Cooper D.S., Doherty G.M., Haugen B.R., Kloos R.T., Lee S.L., Mandel S.L., et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006, 16:1-33.
9. Cooper D.S., Doherty G.D., Haugen B.R., Kloos R.T., Lee S.L., Mandel S.L., et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009, 19:1167-1214.
10. Pacini F., Schlumberger M., Dralle H., Elisei R., Smit J.W., Wiersinga W. European consensus for the management of patients with differentiated thyroid cancer of the follicular epithelium. Eur J Endocrinol 2006, 154:787-903. the European Thyroid Cancer Taskforce.
11. Gómez J.M., Sánchez Franco F. Consideraciones acerca del consenso europeo para el tratamiento del cáncer diferenciado del tiroides. Endocrinol Nutr 2006, 53:427-429.
12. Van den Bruel A., Moreno-Reyes R., Bex M., Daumerie C., Glinoer D. Is the management of thyroid nodules and differentiated thryroid cancer in accordance with recent consensus guidelines?. Results of a national survey. Clin Endocrinol (Oxf) 2008, 68:599-604.
13. Sywak M., Cornford L., Roach P., Stalberg P., Sidhu S., Delbridge L. Routine ipsilateral level VI lymphadenectomy reduces postoperative throglobulin levels in papillary thyroid cancer. Surgery 2006, 1000-1007.
14. Lee Y.S., Kim S.W., Kim S.W., Kim S.K., Kang H.S., Lee E.S., et al. Extent of routine central lymph node dissection with small papillary thyroid carcinoma. Word J Surg 2007, 31:1954-1959.
15. UICC. Sobin LH, Wittekind Ch, editors. TNM Classification of malignant Tumors. 6th edition, Nueva York: Wiley-Liss; 2002. p. 52-56.
16. Sherman S.I., Brierley J.D., Sperling B., Ain K.B., Bigos S.T., Cooper D.S., et al. Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 1998, 83:1012-1021.
17. McGriff N.J., Csako G., Gourgiotis L., Lori C.G., Pucino F., Sarlis N.J. Effects of thyroid suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 2002, 35:554-564.
18. Pujol P., Daures J.P., Nsakala N., Baldeet L., Bringer J., Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996, 81:4318-4323.
19. Reverter J.L. Cáncer de tiroides, levotiroxina y masa ósea. La evidencia, la experiencia y tres preguntas. Endocrinol Nutr 2007, 54:237-240.
20. Reverter J.L., Holgado S., Alonso N., Salinas I., Granada M.L., Sanmartí A. Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma. Endocr Relat Cancer 2005, 12:973-981.
21. Reverter JL, Colomé E, Puig-Domingo M, Julián T, Halperin I, Sanmartí A. Percepción de los endocrinólogos clínicos sobre los potenciales efectos perjudiciales del tratamiento supresor de la TSH en el carcinoma diferenciado de tiroides. Endocrinol Nutr. 2010 (en prensa).
22. Mazzaferri E.L., Robbins R.J., Spencer C.A., Braverman L.E., Pacini F., Wartofsky L., et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003, 88:1433-1441.
23. Robbins R.J., Robbins A.K. Clinical review 156: Recombinant human thyrotropin and thyroid cancer management. J Clin Endocrinol Metab 2003, 88:1933-1938.
24. Luster M., Sherman S.I., Skarulis M.C., Reynols J.R., Lassmann M., Hanscheid H., et al. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging 2003, 30:1371-1377.
25. Mazzaferri EL, Kloos RT. Using recombinant human TSH in the management of well-differentiate thyroid cancer: current strategies and future directions. NCCN Practice Guidelines for Thyroid Cancer. 2000.
26. Mazzaferri EL, Kloos RT. Using recombinant human TSH in the management of well-differentiate thyroid cancer: current strategies and future directions. NCCN Practice Guidelines for Thyroid Cancer. 2000.
27. Haugen B.R., Ridgway E.C., McLaughlin B.A., McDermott M.T. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid 2002, 12:37-43.